Sven Löffeler

7PUBLICATIONS
13CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Peripheral nervous systemMedical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 03, 2024
DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance.

Karolina Cyll, Erik Skaaheim Haug, Manohar Pradhan

|Mar 12, 2024
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).

Sven Löffeler, Helena Bertilsson, Christoph Müller

|Jul 11, 2022
A Norwegian perspective on the Swedish national guidelines on prostate cancer for non-metastatic disease.

Karol Axcrona, Sven Löffeler

|Apr 29, 2022
Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol.

Aino Siltari, Jarno Riikonen, Juha Koskimäki

|Nov 10, 2020
Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test.

Hari T Vigneswaran, Thorgerdur Palsdottir, Henrik Olsson

|Mar 06, 2020
Non-metastatic prostate cancer: rationale for conservative treatment and impact on disease-related morbidity and mortality in the elderly.

Sven Löffeler, Adrian Halland, Haris Fawad

Pageof 2

Frequent Collaborators

2 joint publications

Tobias Nordström

1 joint publications

Harald Weedon-Fekjær

1 joint publications

Christian Beisland

1 joint publications

Hari T Vigneswaran